OraSure Technologies Inc (OSUR)
5.43
-0.07
(-1.27%)
USD |
NASDAQ |
Apr 25, 09:50
OraSure Technologies Research and Development Expense (Quarterly): 6.991M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.991M |
| September 30, 2023 | 8.516M |
| June 30, 2023 | 7.661M |
| March 31, 2023 | 10.56M |
| December 31, 2022 | 8.052M |
| September 30, 2022 | 10.09M |
| June 30, 2022 | 9.463M |
| March 31, 2022 | 8.634M |
| December 31, 2021 | 8.90M |
| September 30, 2021 | 8.596M |
| June 30, 2021 | 7.682M |
| March 31, 2021 | 8.992M |
| December 31, 2020 | 10.46M |
| September 30, 2020 | 8.007M |
| June 30, 2020 | 6.924M |
| March 31, 2020 | 5.644M |
| December 31, 2019 | 6.104M |
| September 30, 2019 | 4.619M |
| June 30, 2019 | 4.535M |
| March 31, 2019 | 4.371M |
| December 31, 2018 | 4.059M |
| September 30, 2018 | 3.855M |
| June 30, 2018 | 4.261M |
| March 31, 2018 | 4.075M |
| December 31, 2017 | 3.829M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.228M |
| June 30, 2017 | 3.338M |
| March 31, 2017 | 2.97M |
| December 31, 2016 | 1.207M |
| September 30, 2016 | 3.196M |
| June 30, 2016 | 2.985M |
| March 31, 2016 | 2.366M |
| December 31, 2015 | 2.693M |
| September 30, 2015 | 2.525M |
| June 30, 2015 | 2.996M |
| March 31, 2015 | 3.44M |
| December 31, 2014 | 3.816M |
| September 30, 2014 | 2.99M |
| June 30, 2014 | 2.771M |
| March 31, 2014 | 2.481M |
| December 31, 2013 | 2.212M |
| September 30, 2013 | 2.67M |
| June 30, 2013 | 2.693M |
| March 31, 2013 | 3.357M |
| December 31, 2012 | 2.894M |
| September 30, 2012 | 2.994M |
| June 30, 2012 | 3.113M |
| March 31, 2012 | 3.444M |
| December 31, 2011 | 3.296M |
| September 30, 2011 | 5.546M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.535M
Minimum
Jun 2019
10.56M
Maximum
Mar 2023
7.917M
Average
8.052M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 684.00M |
| Integra Lifesciences Holdings Corp | 24.28M |
| Insulet Corp | 42.00M |
| Perspective Therapeutics Inc | 6.08M |
| Xtant Medical Holdings Inc | 0.492M |